Abiraterone acetate is a CYP17 inhibitor and is approved by the FDA for mCRPC. It suppresses circulating androgen levels, which has been shown to be immunost...John W
(mcrpc). the drug is the first and only dual action tablet to combine a parp inhibitor with abiraterone acetate, given with prednisone, to treat this indication. this approval follows positive results from the randomised, double-blind, placebo-controlled, multi-centre phase 3 magnitude study, whi...
The FDA has also approved Locametz (kit for the preparation of gallium Ga 68 gozetotide injection). After radiolabeling, this imaging agent may be used to identify PSMA-positive lesions in adult patients with mCRPC through a positron emission tomography (PET) scan. Gallium-68 labeled Locametz c...